Abbott Plans Phase III Study Of Potential First-In-Class Psoriasis Therapy This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Monoclonal antibody ABT-874 reduced psoriasis symptoms significantly in patients in a Phase II study, Abbott reports.